Literature DB >> 23974830

Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.

Tuomas Heikkinen1, Taina Korpela, Rainer Fagerholm, Sofia Khan, Kristiina Aittomäki, Päivi Heikkilä, Carl Blomqvist, Olli Carpén, Heli Nevanlinna.   

Abstract

Abnormal translation of mRNAs frequently occurring during carcinogenesis is among the mechanisms that can affect the expression of proteins involved in tumor development and progression. Eukaryotic initiation factor eIF4E is a key regulator of translation of many cancer-related transcripts and its expression is altered in various cancers and has been associated with worse survival. We determined the eIF4E protein levels using immunohistochemistry (IHC) in 1,233 breast tumors on tissue microarrays. We analyzed the effects of the IHC expression level on tumor characteristics and patient survival, also with stratification by adjuvant chemotherapy treatment. In 1,085 successfully stained tumors, high level of eIF4E protein expression was associated with features of aggressive tumor phenotype, namely grade, estrogen and progesterone receptor negativity, HER2 receptor positivity, and high expression of p53 and Ki67, and with triple negative subtype (p < 0.001). High eIF4E expression was associated with worse breast cancer-specific survival with a hazard ratio (HR) of 1.99 (95 % CI 1.32-3.00, p = 0.0008) and was in a multivariate analysis an independent prognostic factor. High eIF4E expression was associated with worse outcome also after detection of distant metastasis (HR = 1.88, 95 % CI 1.20-2.94, p = 0.0060). In the subgroup analysis the survival effect was strongest among patients treated with anthracycline chemotherapy (HR = 3.34, 95 % CI 1.72-6.48, p = 0.0002), whereas no such effect was seen among patients who had not received anthracycline with significant difference in heterogeneity between the two groups (p = 0.0358). High expression of eIF4E is associated with adverse tumor characteristics and predicts poor breast cancer-specific survival. This effect is emphasized in patients treated with anthracycline chemotherapy. eIF4E as a treatment predictive factor warrants further studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23974830     DOI: 10.1007/s10549-013-2671-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  20 in total

1.  The role of eIF4E in response and acquired resistance to vemurafenib in melanoma.

Authors:  Yao Zhan; Michael S Dahabieh; Arjuna Rajakumar; Monica C Dobocan; Marie-Noël M'Boutchou; Christophe Goncalves; Shiru L Lucy; Filippa Pettersson; Ivan Topisirovic; Léon van Kempen; Sonia V Del Rincón; Wilson H Miller
Journal:  J Invest Dermatol       Date:  2015-01-23       Impact factor: 8.551

2.  Prognostic significance of eukaryotic initiation factor 4E in hepatocellular carcinoma.

Authors:  Xue-Mei Jiang; Xiang-Nan Yu; Ren-Zheng Huang; Hai-Rong Zhu; Xiao-Peng Chen; Ju Xiong; Zheng-Yi Chen; Xiao-Xi Huang; Xi-Zhong Shen; Ji-Min Zhu
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-06       Impact factor: 4.553

3.  Targeted Dual pH-Sensitive Lipid ECO/siRNA Self-Assembly Nanoparticles Facilitate In Vivo Cytosolic sieIF4E Delivery and Overcome Paclitaxel Resistance in Breast Cancer Therapy.

Authors:  Maneesh Gujrati; Amita M Vaidya; Margaret Mack; Dayton Snyder; Anthony Malamas; Zheng-Rong Lu
Journal:  Adv Healthc Mater       Date:  2016-10-10       Impact factor: 9.933

4.  Phospho-4e-BP1 and eIF4E overexpression synergistically drives disease progression in clinically confined clear cell renal cell carcinoma.

Authors:  Lee Campbell; Bharat Jasani; David Fr Griffiths; Mark Gumbleton
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

5.  mTORC1 induces eukaryotic translation initiation factor 4E interaction with TOS-S6 kinase 1 and its activation.

Authors:  Sheikh Tahir Majeed; Asiya Batool; Rabiya Majeed; Nadiem Nazir Bhat; Muhammad Afzal Zargar; Khurshid Iqbal Andrabi
Journal:  Cell Cycle       Date:  2021-05-03       Impact factor: 4.534

6.  EIF4EBP1 overexpression is associated with poor survival and disease progression in patients with hepatocellular carcinoma.

Authors:  Yin-Lian Cha; Pin-Dong Li; Lin-Jing Yuan; Mei-Yin Zhang; Yao-Jun Zhang; Hui-Lan Rao; Hui-Zhong Zhang; X F Steven Zheng; Hui-Yun Wang
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

7.  Predictive value of phosphorylated mammalian target of rapamycin for disease-free survival in breast cancer patients receiving neoadjuvant chemotherapy.

Authors:  Shuo Wang; Yiqun Sun; Anning He; Caiwei Zheng; Xinyu Zheng
Journal:  Oncol Lett       Date:  2014-09-18       Impact factor: 2.967

8.  Overexpression of eIF4E in colorectal cancer patients is associated with liver metastasis.

Authors:  Tao Xu; Yuanyuan Zong; Lipan Peng; Shuai Kong; Mingliang Zhou; Jianqiang Zou; Jinglei Liu; Ruizheng Miao; Xichao Sun; Leping Li
Journal:  Onco Targets Ther       Date:  2016-02-19       Impact factor: 4.147

9.  Knockdown of eukaryotic translation initiation factor 4E suppresses cell growth and invasion, and induces apoptosis and cell cycle arrest in a human lung adenocarcinoma cell line.

Authors:  Baofu Chen; Bo Zhang; Lilong Xia; Jian Zhang; Yu Chen; Quanteng Hu; Chengchu Zhu
Journal:  Mol Med Rep       Date:  2015-10-21       Impact factor: 2.952

10.  RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition.

Authors:  Philip Earwaker; Caroline Anderson; Frances Willenbrock; Adrian L Harris; Andrew S Protheroe; Valentine M Macaulay
Journal:  PLoS One       Date:  2018-02-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.